SKYESkye Bioscience, Inc.vs its industry peers
A metric-by-metric comparison of Skye Bioscience, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SKYEThis | $73M#4 | — | — | — | — | -110.5%#5 | — | — | — | — | -93.7%#3 | — |
| VRCA | $79M#1 | — | 18.2x#3 | 2.2x#1 | 370.2%#1 | 76.6%#1 | -34.2%#1 | -415.6%#3 | -36.1%#1 | — | -9.7%#1 | — |
| LNAI | $78M#2 | 1.1x#1 | — | 2390.9x#2 | -47.8%#2 | -101.3%#4 | -576678.5%#2 | — | — | 5#1 | -85.9%#2 | — |
| ACRV | $78M#3 | — | 0.9x#1 | — | — | 3.3%#2 | — | -89.9%#1 | — | — | — | — |
| PMVP | $72M#5 | — | 1.0x#2 | — | — | -32.0%#3 | — | -108.7%#2 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice